African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2248

Full Length Research Paper

Synergistic anticancer effects of valproic acid, atorvastatin and pioglitazone in human malignant and murine cells

André L. S. Barros
  • André L. S. Barros
  • Bioassays Laboratory for Pharmaceutical Research, Antibiotics Department, Biological Sciences Center, Federal University of Pernambuco, Recife, Brazil.
  • Google Scholar
Jaciana S. Aguiar
  • Jaciana S. Aguiar
  • Bioassays Laboratory for Pharmaceutical Research, Antibiotics Department, Biological Sciences Center, Federal University of Pernambuco, Recife, Brazil.
  • Google Scholar
Larissa C. C. Araújo
  • Larissa C. C. Araújo
  • Bioassays Laboratory for Pharmaceutical Research, Antibiotics Department, Biological Sciences Center, Federal University of Pernambuco, Recife, Brazil.
  • Google Scholar
Christina A. Peixoto
  • Christina A. Peixoto
  • Ultrastructure Laboratory, Aggeu Magalhães Research Center, Recife, Brazil.
  • Google Scholar
Paloma L. de Medeiros
  • Paloma L. de Medeiros
  • Hystology and Embryology Department, Biological Sciences Center, Federal University of Pernambuco, Recife, Brazil.
  • Google Scholar
Maria Teresa J. A. Catanho
  • Maria Teresa J. A. Catanho
  • Biophysics and Radiology Department, Biological Sciences Center, Federal University of Pernambuco, Recife, Brazil.
  • Google Scholar
Teresinha Gonçalves da Silva
  • Teresinha Gonçalves da Silva
  • Bioassays Laboratory for Pharmaceutical Research, Antibiotics Department, Biological Sciences Center, Federal University of Pernambuco, Recife, Brazil.
  • Google Scholar


  •  Accepted: 30 December 2013
  •  Published: 15 January 2014

References

Al-Harbi MM, Al-Gharably NM, Al-Shabanah OA, Al-Bekairi AM, Osman AM, Tawfik HN (1992). Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother. Pharmacol. 31:200-204.
Crossref
 
Bardou M, Barkun A, Martel M (2010). Effect of statin therapy on colorectal cancer. Gut 59:1572-1585.
Crossref
 
Bezerra DP, Castro FO, Alves APNN, Pessoa C, Moraes MO, Silveira ER (2008). In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine. J. Appl. Toxicol. 28:156-163.
Crossref
 
Blanquicett C, Roman J, Michael HC (2008). Thiazolidinediones as anti-cancer agents. Cancer Ther. 6:25–34.
Pubmed
 
Bolden JE, Peart MJ, Johnstone RW (2006). Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug. Discov. 5:769-784.
Crossref
 
Cafforio P, Dammacco F, Gernone A, Silvestris F (2005). Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26:883–891.
Crossref
 
Cerbone A, Toaldo C, Laurora S, Briatore F, Pizzimenti S, Dianzani MU, Ferretti C, Barrera G (2007). 4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, apoptosis in colon cancer cells. Free Radic. Biol. Med. 42:1661–1670.
Crossref
 
Chen J, Lan T, Hou J, Zhang J, An Y, Tie L, Pan Y, Liu J, Li X (2012). Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1. Int. J. Biochem. Cell Biol. 44(5):759-769.
Crossref
 
Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B (2013). Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Cell Death Dis. 9:e814.
Crossref
 
Chou TC (1991). The median-effect principle and the combination index for quantitation of synergism and antagonism, in Synergism and Antagonism in Chemotherapy. San Diego: Academic press. pp. 61-102.
 
Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ (2000). Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk. Lymphoma 40:167–178.
Pubmed
 
Farley-Hills E, Sivasankar R, Martin M (2004). Fatal liver failure associated with pioglitazone. BMJ 329:429.
Crossref
 
Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M (2007). Effect of simvastatin and/or pioglitazona on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. Metabolism 56:491-496.
Crossref
 
Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, Weber M, Müller J, Konrad T, Hanefeld M (2008). Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab. Vasc. Dis. Res. 5:298-303.
Crossref
 
Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, Banks KM (2008). Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl. Acad. Sci. 105:11317–11322.
Crossref
 
Gan Y, Wang J, Coselli J, Wang XL (2008). Synergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells. Biochem. Biophys. Res. Commun. 365:386-392.
Crossref
 
Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH, Schlegel U, Heneka MT (2006). Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol. Pharmacol. 70:1524-1533.
Crossref
 
Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T (2007). Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J. Am. Coll. Cardiol. 49:290-297.
Crossref
 
Heaney AP (2004). Novel pituitary ligands: peroxisome proliferator-activated receptor-γ. Pituitary 6:153-159.
Crossref
 
Kaufman DC, Chabner BA (2001). Clinical strategies for cancer treatment: the role of drugs. In: Chabner, BA Longo DL (eds.), Cancer Chemotherapy & Biotherapy. Philadelphia: Lippincott Williams & Wilkins. pp. 1–16.
 
Koeffler HP (2003). Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res. 9:1-9.
Pubmed
 
Li MY, Deng H, Zhao JM, Dai D, Tan XY (2003). PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J. Gastroenterol. 9:1220-1226.
Pubmed
 
Li MY, Yuan H, Ma LT, Kong AW, Hsin MK, Yip JH, Underwood MJ, Chen GG (2010). Roles of peroxisome proliferator-activated receptor-alpha and -gamma in the development of non-small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 43:674-683.
Crossref
 
Lichtor T, Spagnolo A, Glick RP, Feinstein DL (2008). PPAR-γ Thiazolidinedione agonists and immunotherapy in the treatment of brain tumors. PPAR Res. 547470.
Crossref
 
Liu T, Kuljaca S, Tee A, Marshall GM (2006). Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev. 32:157–165.
Crossref
 
Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA (2008). The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27:123-135.
Crossref
 
Marchion D, Münster P (2007). Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther. 7:583–598.
Crossref
 
Marks PA (2010). The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 19:1049–1066.
Crossref
 
Martelli ML, Iuliano R, Le Pera I, Sama' I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M, Fusco A (2002). Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab. 87:4728-4735.
Crossref
 
Martirosyan A, Clendening JW, Goard CA, Penn LZ (2010). Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 10:103.
Crossref
 
Meral K, Ersoz M, Altiok N (2007). Simvastatin induces apoptosis in human breast cancer cells: p53 and androgen receptor independent pathway requiring signalling through JNK. Cancer Lett. 250:220-228.
Crossref
 
Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 16:55–63.
Crossref
 
Mrówka P, GÅ‚odkowska E, MÅ‚ynarczuk-BiaÅ‚y I, BiaÅ‚y L, Kuckelkorn U, Nowis D, Makowski M, Legat M, GoÅ‚ab J (2008). Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome. Acta Biochim. Pol. 55:75–84.
Pubmed
 
Munster P, Marchion D, Bicaku E, Lacevic M, Kim J. Centeno JB (2009). Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 15:2488–2496.
Crossref
 
Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T (2001). Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 86:2170-2177.
Crossref
 
Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T (2011). Statins and prostate cancer: molecular and clinical aspects. Eur. J. Cancer 47:819-830.
Crossref
 
Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP (2007). Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 13:3605-3610.
Crossref
 
Reynolds CP, Maurer BJ (2005). Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol. Med. 110:173–183.
Pubmed
 
Sassano A, Platanias LC (2008). Statins in tumor suppression. Cancer Lett. 260:11–19.
Crossref
 

Sławińska A, Kandefer-Szerszeń M (2008). The anticancer properties of statins. Postepy Hig. Med. Dosw. 62:393-404.

Pubmed

 
Valentini A, Gravina P, Federici G, Bernardini S (2007). Valproic acid induces apoptosis, p(16INK4A) upregulation and sensitization to chemotherapy in human melanoma Cells. Cancer Biol. Ther. 6:185–191.
Crossref
 
Xie C, Edwards H, Lograsso SB, Buck SA, Matherly LH, Taub JW, Ge Y (2012). Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatr. Blood Cancer 59:1245-1251.
Crossref
 
Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y,  Nishida S (2011). Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranylpyrophosphate biosynthesis in glioblastoma. J. Exp. Clin. Cancer Res. 30:74.
Crossref
 
Zang C, Liu H, Waechter M, Eucker J, Bertz J, Possinger K, Koeffler HP, Elstner E (2006). Dual PPARalpha/ gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. Cell Cycle 5:2237–2243.
Crossref